Fidelis Capital Partners’s AbbVie ABBV Stock Holding History

Fidelis Capital Partners’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$9.73M	Buy	38,686 +4,950	+15%	+$1.06M	0.56%	42
2026 Q1	$7.34M	Sell	33,736 -385	-1%	-$85.4K	0.52%	40
2025 Q4	$7.8M	Buy	34,121 +1,796	+6%	+$409K	0.57%	38
2025 Q3	$7.48M	Buy	32,325 +3,951	+14%	+$805K	0.58%	35
2025 Q2	$5.57M	Sell	28,374 -145	-0.5%	-$26.9K	0.51%	38
2025 Q1	$5.31M	Buy	28,519 +1,560	+6%	+$303K	0.56%	35
2024 Q4	$5.13M	Buy	26,959 +2,214	+9%	+$407K	0.51%	39
2024 Q3	$4.65M	Buy	24,745 +1,778	+8%	+$332K	0.55%	35
2024 Q2	$4.31M	Buy	22,967 +2,347	+11%	+$389K	0.61%	32
2024 Q1	$3.75M	Buy	20,620 +4,456	+28%	+$768K	0.57%	35
2023 Q4	$2.5M	Buy	16,164 +2,607	+19%	+$380K	0.55%	36
2023 Q3	$2.02M	Buy	13,557 +2,187	+19%	+$321K	0.69%	31
2023 Q2	$1.53M	Buy	11,370 +678	+6%	+$99.4K	0.56%	41
2023 Q1	$1.58M	Buy	10,692 +7,602	+246%	+$1.16M	0.67%	35
2022 Q4	$500K	Buy	+3,090	New	+$474K	0.59%	58

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelis Capital Partners's ABBV Position: Q2 2026 in Review

Fidelis Capital Partners increased its AbbVie (ABBV) stake by 15% in Q2 2026, buying an estimated $1.06M and bringing the position to 38,686 shares worth $9.73M. The position accounts for 0.56% of the portfolio, ranked #42.

Fidelis Capital Partners first reported a position in ABBV in Q4 2022 and has held it in 15 quarters since. 4,234 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

Fidelis Capital Partners held 38,686 shares of AbbVie worth $9.73M as of Q2 2026.
Fidelis Capital Partners bought 4,950 AbbVie shares in Q2 2026, an estimated $1.06M.
AbbVie made up 0.56% of Fidelis Capital Partners's portfolio in Q2 2026, its #42 holding.
Fidelis Capital Partners first reported a position in AbbVie in Q4 2022 and has held it in 15 quarters since.
4,234 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Fidelis Capital Partners's 13F filing for Q2 2026, filed 13 Aug 2026.